Cardiac Resynchronization Therapy (CRT) Market Insights, Competitive Landscape and Market Forecast 2024-2030
December 09, 2024 09:49 ET
|
Research and Markets
Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy (CRT) - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ...
Renova Therapeutics Appoints Dr. Vijay Mahant as Its CEO
December 09, 2021 09:00 ET
|
Renova Therapeutics
CARLSBAD, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Dr. Mahant brings a wealth of knowledge and experience to his role as the CEO. He is a scientist, an inventor (awarded 32 international patents)...
AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure
February 04, 2020 08:05 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor...
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
April 15, 2019 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...
Mesoblast Reports Strong Half-Year Financial Results
February 25, 2014 17:00 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and...
Boardroom Radio Interview with Mesoblast Chief Executive
February 02, 2014 20:06 ET
|
Mesoblast
NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...
FDA CLEARS COMMENCEMENT OF PHASE 3 CHRONIC HEART FAILURE TRIAL USING MESOBLAST'S PROPRIETARY CELLS
October 30, 2013 18:41 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Food and Drug...